Evidence map›Paper›PMID 23397083›Full record

ArticleMedical oncology (Northwood, London, England)2013

Sensitization of lung cancer cells to cisplatin by β-elemene is mediated through blockade of cell cycle progression: antitumor efficacies of β-elemene and its synthetic analogs.

Q Quentin Li, Gangduo Wang, Furong Huang, Jueli M Li, Christopher F Cuff, Eddie Reed

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03123484 (β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer), which is not on this map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03123484 phase2unknown statusnot on this mapstarted 2017, after this paper: background citation

β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

TypeinterventionalSponsorChina Medical University, ChinaRan2017 to 2019Enrolled80ConditionsNon Small Cell Lung CancerArmsβ-elemene, EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Active Ingredients from Chinese Medicine for Combination Cancer Therapy.International journal of biological sciences · 2023
    Review
  5. Review
  6. Article
  7. Article
  8. An ATFCancer biology & medicine · 2020
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Inhibitory effect of β-elemene on human breast cancer cells.International journal of clinical and experimental pathology · 2014
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Q Quentin LiWest Virginia University School of Medicine, Morgantown, WV 26506, USA. liquenti@mail.nih.gov
Gangduo Wang
Furong Huang
Jueli M Li
Christopher F Cuff
Eddie Reed
West Virginia University · USNational Cancer Institute · USUniversity of Maryland, Baltimore · US

Funding

THE ROLE OF HEF1 PROTEIN IN INVASION OF METASTATIC BREAST CANCERP20RR016440 · NCRR · WEST VIRGINIA UNIVERSITY · PI CUFF, CHRISTOPHER F · 2001 to 2010
$22.8M
NCRR NIH HHS P20 RR016440NCRR NIH HHS P20RR16440-010003NCRR NIH HHS P20RR16440-020003NCRR NIH HHS P20RR16440-030003NCRR NIH HHS P20RR16440-040003
6 · The paper itself

Abstract

The development of effective agents for overcoming platinum chemoresistance in lung carcinoma continues to have high priority. We have demonstrated recently that β-elemene, a novel antitumor compound, enhances cisplatin activity by triggering lung cancer cell death via apoptosis. Here, we investigated whether β-elemene acts synergistically with cisplatin to inhibit non-small cell lung cancer (NSCLC) cell proliferation by blocking cell cycle progression. β-Elemene substantially increased the suppressive effect of cisplatin on cell growth and proliferation in the NSCLC cell lines H460 and A549. Furthermore, β-elemene augmented cisplatin in the cell cycle arrest of NSCLC cells at G(2)/M. This was associated with upregulated checkpoint kinase (CHK2) expression and reduced CDC2 activity (i.e., increased phosphorylation of CDC2 on Tyr-15 and decreased phosphorylation of CDC2 on Thr-161). Moreover, β-elemene and cisplatin in combination clearly decreased the protein levels of cyclin B1 and CDC25C and increased the levels of p21(Cip1/Waf1), p27(Kip1), and GADD45 in these cells, compared with the effects of either agent alone at the same concentration. These results suggest that the β-elemene-enhanced inhibitory effect of cisplatin on lung carcinoma cell proliferation is regulated by a CHK2-mediated CDC25C/CDC2/cyclin B1 signaling pathway and leads to the blockade of cell cycle progression at G(2)/M. A comparison of the cytotoxic efficacies of β-elemene and three synthetic analogs (β-elemenol, β-elemenal, and β-elemene fluoride) in the two lung cancer cell lines revealed that β-elemenol and β-elemene fluoride had the same antitumor efficacy as β-elemene, whereas β-elemenal was appreciably more potent than β-elemene. Thus, although all three synthetic analogs of β-elemene considerably suppressed NSCLC cell growth and proliferation, β-elemenal may have greater potential as an anticancer alternative to β-elemene in treating lung cancer and other tumors.

Indexed as

Antineoplastic Agents, PhytogenicCarcinoma, Non-Small-Cell LungCDC2 Protein KinaseCell CycleCell Line, TumorCell ProliferationCheckpoint Kinase 2CisplatinCyclin BCyclin-Dependent KinasesG2 Phase Cell Cycle CheckpointsHumansLung NeoplasmsPhosphorylationProtein Serine-Threonine KinasesSesquiterpenesAntineoplastic Agents, Phytogenicbeta-elemeneCDC2 Protein KinaseCDK1 protein, humanCheckpoint Kinase 2CHEK2 protein, humanCisplatinCyclin BCyclin-Dependent KinasesProtein Serine-Threonine KinasesSesquiterpenes

Identifiers

PMID23397083
OpenAlexW2043737875

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.